Targeted protein degradation using small molecules

Learn how Protacs work for targeted protein degradation to widen the spectrum of targetable proteins Targeted protein degradation (TPD) is an emerging drug discovery strategy that allows access to difficult-to-treat diseases. While traditional small-molecule drugs may only allow access to ~20% of the proteome, degradation techniques may open the door to the other 80%. Proteolysis targeting chimeras (Protacs) are an attractive new means of protein degradation, and work catalytically at sub-stoichiometric levels over an extended length of time. These tools have the potential to widen the spectrum of targetable proteins, including proteins that have proven intractable to traditional approaches.